These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 1323809

  • 1. Carboplatin/etoposide/vincristine therapy in small cell lung cancer.
    Gatzemeier U, von Pawel J, Laumen R, Hossfeld DK, Neuhauss R, Reck M, Lenaz L.
    Oncology; 1992; 49 Suppl 1():25-33. PubMed ID: 1323809
    [Abstract] [Full Text] [Related]

  • 2. Phase II and III studies with carboplatin in small cell lung cancer.
    Gatzemeier U, Hossfeld DK, Neuhauss R, Reck M, Achterrath W, Lenaz L.
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):28-36. PubMed ID: 1329220
    [Abstract] [Full Text] [Related]

  • 3. Carboplatin in small cell lung cancer.
    Gatzemeier U, Hossfeld DK, Neuhauss R, Reck M, Achterrath W, Lenaz L.
    Semin Oncol; 1991 Feb; 18(1 Suppl 2):8-16. PubMed ID: 1846981
    [Abstract] [Full Text] [Related]

  • 4. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S, Norwegian Lung Cancer Study Group.
    J Clin Oncol; 2002 Dec 15; 20(24):4665-72. PubMed ID: 12488411
    [Abstract] [Full Text] [Related]

  • 5. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
    Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, Ulm K, Hessler S, Gatzemeier U.
    Lung Cancer; 2006 Jul 15; 53(1):67-75. PubMed ID: 16713013
    [Abstract] [Full Text] [Related]

  • 6. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group.
    Lung Cancer; 2005 May 15; 48(2):251-61. PubMed ID: 15829326
    [Abstract] [Full Text] [Related]

  • 7. Comparison of carboplatin/etoposide/vincristine with cisplatin/etoposide as combination chemotherapy for small cell lung cancer.
    Kumagai M, Kutsuzawa T, Fuyuno G, Kondo T, Shioya S, Ohta Y.
    Tokai J Exp Clin Med; 1995 Dec 15; 20(4-6):209-14. PubMed ID: 8956462
    [Abstract] [Full Text] [Related]

  • 8. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
    Lee YC, McCrystal MR, Christmas TI.
    N Z Med J; 1998 Nov 27; 111(1078):451-2, 453-4. PubMed ID: 9891564
    [Abstract] [Full Text] [Related]

  • 9. Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer.
    Gatzemeier U, Hossfeld DK, Neuhauss R, Reck M, Achterrath W, Lenaz L.
    J Clin Oncol; 1992 May 27; 10(5):818-23. PubMed ID: 1314891
    [Abstract] [Full Text] [Related]

  • 10. Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial.
    Gatzemeier U, Pawel JV, Laumen R, Hossfeld DK, Neuhauss R.
    Semin Oncol; 1994 Jun 27; 21(3 Suppl 6):31-5. PubMed ID: 8052871
    [Abstract] [Full Text] [Related]

  • 11. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D, Mari D, Graziano F, Isidori P, Cetto G, Pasini F, Santo A, Cellerino R.
    Cancer; 1997 Dec 15; 80(12):2222-9. PubMed ID: 9404698
    [Abstract] [Full Text] [Related]

  • 12. Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients.
    Hirsch FR, Osterlind K, Jeppesen N, Dombernowsky P, Ingeberg S, Sorensen PG, Kristensen C, Hansen HH.
    Ann Oncol; 2001 May 15; 12(5):647-53. PubMed ID: 11432623
    [Abstract] [Full Text] [Related]

  • 13. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
    Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Lange W, Mertelsmann R.
    Ann Oncol; 1999 May 15; 10(5):561-7. PubMed ID: 10416006
    [Abstract] [Full Text] [Related]

  • 14. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
    Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, Ulm K, Hessler S, Gatzemeier U.
    J Natl Cancer Inst; 2003 Aug 06; 95(15):1118-27. PubMed ID: 12902441
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M, Erturk D.
    Saudi Med J; 2003 Jun 06; 24(6):628-31. PubMed ID: 12847592
    [Abstract] [Full Text] [Related]

  • 16. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK, Nicaise C, Lawson R, Maroun JA, Comis R, Speer J, Luedke D, Hurtubise M, Lanzotti V, Goodlow J.
    J Clin Oncol; 1989 Apr 06; 7(4):450-6. PubMed ID: 2538577
    [Abstract] [Full Text] [Related]

  • 17. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R, Flechtner H, Goerg R, Becker H.
    Semin Oncol; 1989 Feb 06; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [Abstract] [Full Text] [Related]

  • 18. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D, Graziano F, Mari D, Cetto G, Pasini F, Antonio S, Isidori P, Gasparini S.
    Anticancer Res; 1994 Feb 06; 14(5B):2221-7. PubMed ID: 7840527
    [Abstract] [Full Text] [Related]

  • 19. Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer.
    Bishop JF, Kefford R, Raghavan D, Zalcberg J, Stuart-Harris R, Ball D, Olver IN, Friedlander M, Bull C, Yuen K.
    Cancer Chemother Pharmacol; 1990 Feb 06; 25(5):367-70. PubMed ID: 2155064
    [Abstract] [Full Text] [Related]

  • 20. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S.
    J Clin Oncol; 1987 Dec 06; 5(12):1880-9. PubMed ID: 2824710
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.